by Year

2017

2017

EHA 2017 22nd Congress of the European Hematology Association, Madrid, Spain. PRELIMINARY RESULTS FROM A LONG-TERM REPEAT DOSE TOXICITY AND TOXICOKINETIC STUDY OF ANF-RHO, A NOVEL ANTI-NEUTROPENIC FACTOR; USE OF PEGYLATED-CARBOXYHEMOGLOBIN BOVINE FOR THE TREATMENT OF SICKLE CELL DISEASE ASSOCIATED LEG ULCERS: RESULTS FROM A PHASE 2 SAFETY STUDY

FSCDR 2017 11th Annual Symposium. Fort Lauderdale, Florida, USA. A Phase 2 Safety Study of SANGUINATE in Patients with Leg Ulcers; SANGUINATE Returns RBCs To More Normal Morphology In Patients With VOC

SCCM (Society of Critical Care Medicine) 2017 46th Critical Care Congress, January 21-25, 2017.  Honolulu, Hawaii, USA. Treatment of severe anemia with SANGUINATE in patients unable to receive red blood cell transfusion

Global Sickle Cell 2017, February 21-274, 2017.  Bhubaneswar, India.  SANGUINATE for the Treatment of Sickle Cell Disease

AST (American Society of Transplantation) 2017, February 23-25, 2017.  Phoenix, Arizona

2016

2016

AABB 2016. October 22-25, 2016. Orlando, Florida. Compassionate, Investigational Use of SANGUINATE™ (PEGylated Carboxyhemoglobin bovine) in a Jehovah’s Witness Patient With Hematemesis

American Society Of Clinical Oncology (ASCO) Annual Meeting 2016. Jun 03 – 07, 2016. Chicago, IL.  Phase 1 Pharmacokinetic and Pharmacodynamic Results of Novel Anti-Neutropenic Factor for the Prevention and Treatment of Febrile Neutropenia

Brazilian Congress of Hematology, Hemotherapy and Cell Therapy (HEMO 2016). November 10-13, 2016.  Florianópolis, Brazil. PEG-CoHb Mediated CO And Oxygen Transfer To Hypoxic Rbcs Prevent, Slow, And/Or Reverse Sickling In Vitro: Implications For Clinical Utility In SCD

22nd Congress of the European Hematology Association. June 9-12, 2016. Copenhagen Denmark. Development Of A Novel Anti-Neutropenic Factor Clinical Candidate For Hematopoiesis Deficiencies; Rapid Reversal Of Red Blood Cell Sickling Promoted By Pegylated Carboxyhemoglobin Bovine Gas Transfer Properties;  Use Of A Pegylated Carboxyhemoglobin Bovine In Severe Life-Threatening Anemia

Experimental Biology Meeting. April 2-6, 2016. San Diego CA. Systemic and Microcirculatory Effects of Severe Hemorrhage and Resuscitation Using a PEGylated Carboxyhemoglobin (PEG-COHb)

Foundation for Sickle Cell Research Symposium. April 14-17, 2016. Ft. Lauderdale FL. SANGUINATE-Mediated Transfer of Oxygen and Carbon Monoxide Can Rapidly Unsickle Red Blood Cells and Reduce the systemic Inflammatory Response

7th Euro-Global Summit on Toxicology and Applied Pharmacology. October 24-26, 2016. Rome Italy. Toxicology Studies and results for detrmining Safety, Toxicity and ToxicoKinetic of ANF-RHO™,  A Novel Anti-Neutropenic Factor; Results From A Long-term Repeat Dose Toxicity and ToxicoKinetic Study of ANF-Rho,

Pan Arab Hematology Congress.  February 13, 2016. Cairo Egypt. Phase II interim results of a therapeutic agent for Thalassemia.  Pan Arab Hematology Congress.  February 13, 2016. Cairo Egypt.  In Vitro Unsickling and Anti-inflammatory activity by SANGUINATE™ mediated gas transfer

3rd Annual Sickle Cell Disease Therapeutics Conference. September 15, 2014. New York City. Treating the Comorbidities of Sickle Cell Disease

Society for Critical Care Anesthesiologists 29th Annual Meeting. (SOCCA) May 20, 2016. San Francisco CA. Bovine Hemoglobin in Place of Human Blood in Jehovah’s Witness: A Case Report

2015

2015

BioNJ’s 22nd Annual Dinner Meeting, Networking Event and Innovation Celebration honoring Dr. Abraham Abuchowski, Prolong’s CEO/CSO, February 5, 2015

ASCO (American Society of Clinical Oncology) Annual Meeting May 29-June 2, 2015.  Chicago, Illinois. Potential use of PEG-HbCO in severe anemia

European Hematology Association (EHA) June 11-14, 2015.  Vienna, Austria. Development of a Novel Anti-Neutropenic Factor Clinical Candidate For Hematopoiesis Deficiencies, Use Of A Pegylated Carboxyhemoglobin Bovine In Severe Life-Threatening Anemia, Rapid Reversal Of Red Blood Cell Sickling Promoted By Pegylated Carboxyhemoglobin Bovine Gas Transfer Properties

“XV ISBS 2015-The XVth International Symposium on Blood Substitutes and Oxygen Therapeutics” June 21-24, 2015.  Lund, Sweden. SANGUINATE™: A CO/O2 delivery therapeutic for the treatment of anemic and ischemic disorders

Fourth Annual Sickle Cell Disease Conference Sept 2-3, 2015.  New York, NY

Vasospasm 2015. Sept 17-19, 2015.  Nagano, Japan. Safety of SANGUINATE™ (Pegylated Carboxy-Hemoglobin Bovine) Infusion in Patients at Risk for Delayed Cerebral Ischemia after Subarachnoid Hemorrhage

2nd Pan-Asian Conference on Haemoglobinopathies and Rare Anaemias Sept 26-27, 2015.  Ha Noi, Vietnam

ASH (American Society of Hematology) Annual Meeting Dec 5-8, 2015.  Orlando, Florida.   ANF-Rho: A dose-ranging Phase I study to determine safety, pharmacokinetics and pharmacodynamics in Healthy Volunteers, A Doppler Defined, Repeat Dose, Safety Study, of PEG-COHb in β Thalassemia Intermedia (TI) Patients with Pulmonary Hypertension (PHT), PEG-COHb Mediated Carbon Monoxide and Oxygen Transfer to Hypoxic Red Blood Cells Prevent, Slow, and/or Reverse Sickling in vitro

2014

2014

BioNJ Partnering Conference. March 2014. Princeton, NJ.  Glenn Kazo, President

Sachs Cancer Bio Partnering and Investment Forum. March 19, 2014. New York, NY, Dr. Ronald Jubin, Vice President – R&D

Foundation for Sickle Cell Research. April 10 – 13, 2014. Hollywood, Florida, USA, A Case Study of SANGUINATE™ in a Patient with a Comorbidity Due to an Underlying Hemoglobinopathy. Dr. D. Parmar. Director of Clinical Operations;  Compassionate Use of SANGUINATE™ in Acute Chest Syndrome. Dr. Yathreb Alaali. Henry Ford Hospital , Pulmonary Critical Care Medicine Fellow

3rd Annual Sickle Cell Disease Therapeutics Conference. September 15, 2014. New York City. Glenn Kazo. President

SCD Association of America. Annual Convention October 1-4, 2014. Baltimore, MD.  SANGUINATE™: A Novel Therapeutic Agent For The Treatment Of Comorbidities Associated With Scd. Dr. Hemant Misra. VP Clinical Development

Toxicology and Applied Pharmacology Conference. October 20-22, 2014. Stokie, IL. Toxicology Study Design and Results for Determining Safety of a Therapeutic Dual Carbon Monoxide and Oxygen Delivery Agent. Dr. Hemant Misra. VP Clinical Development

AABB Annual Meeting. October 25-28, 2014. Philadelphia, PA.  SANGUINATE™ as an Acute Therapy for Anemia: Report of Two Patients. Dr. Abraham Abuchowski. CEO/CSO

Brazillian Congress of Hematology. November 9-12, 2014. Brazil.  Use Of SANGUINATE™ To Treat The Comorbidities Of Sickle Cell Disease. Dr. Hemant Misra. VP Clinical Development

Publications

Title: SANGUINATE (PEGylated Carboxyhemogolobin Bovine): Mechanism of Action and Clinical Update

Author: Abraham Abuchowski

Journal: Artificial Organs 2017 Apr;41(4):346-350

DOI: 10.1111/aor.12934

EPub: APR201701

PMID: 28397407

Abstract Link: https://www.ncbi.nlm.nih.gov/pubmed/?term=28397407

Full Text Article: 2017/04/SANGUINATE_PEGylated-Carboxyhemoglobin-Bovine_Mechanism-of-Action-and-Clinical-Update.pdf


Title: PEGylated Bovine Carboxyhemoglobin (SANGUINATE™): Results of Clinical Safety Testing and Use in Patients

Author: Abuchowski A

Journal: Adv Exp Med Biol. 2016;876:461-7

DOI: 10.1007/978-1-4939-3023-4_58

PMID: 26782246

Link: https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1007%2F978-1-4939-3023-4_58


Title: Use of hyperbaric oxygen therapy and PEGylated carboxyhemoglobin bovine in a Jehovah’s Witness with life-threatening anemia following postpartum hemorrhage

Author: Thenuwara K, Thomas J, Ibsen M, Ituk U, Choi K, Nickel E, Goodheart MJ

Journal: Int J Obstet Anesth. 2017 Feb;29:73-80

DOI: 10.1016/j.ijoa.2016.10.006

EPub: 24OCT2016

PMID: 27890467

Link: https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016%2Fj.ijoa.2016.10.006


Title: A Phase Ib open label, randomized, safety study of SANGUINATE™ in patients with sickle cell anemia

Author: Misra H, Bainbridge J, Berryman J, Abuchowski A, Galvez KM, Uribe LF, Hernandez AL, Sosa NR

Journal: Rev Bras Hematol Hemoter. 2017 Jan – Mar;39(1):20-27

DOI: 10.1016/j.bjhh.2016.08.004

EPub: 20OCT2016

PMID: 28270341

Link: https://www.ncbi.nlm.nih.gov/pubmed/?term=28270341


Title: Sanguinate’s effect on pial arterioles in healthy rats and cerebral oxygen tension after controlled cortical impact

Author: Mullah SH, Abutarboush R, Moon-Massat PF, Saha BK, Haque A, Walker PB, Auker CR, Arnaud FG, McCarron RM, Scultetus AH

Journal: Microvascular Research. 2016 Sep;107:83-90

DOI: 10.1016/j.mvr.2016.06.001

EPub: 07JUN2016

PMID: 27287870

Link: https://www.ncbi.nlm.nih.gov/pubmed/27287870


Title: Determination of methemoglobin and hemoglobin levels in small volume samples

Author: Arnaud F, Higgins A, McCarron R, Moon-Massat PF

Journal: Artificial Cells, Nanomedicine, and Biotechnology 2017 Feb;45(1):58-62

DOI: 10.3109/21691401.2016.1138490

EPub: 02MAR2016

PMID: 26934005

Link: https://www.ncbi.nlm.nih.gov/pubmed/26934005


Title: PEGylated Bovine Carboxyhemoglobin (SANGUINATE™): Results of Clinical Safety Testing and Use in Patients

Author: Abuchowski A

Journal: Adv Exp Med Biol. 2016;876:461-7

DOI: 10.1007/978-1-4939-3023-4_58

PMID: 26782246

Link: https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1007%2F978-1-4939-3023-4_58


Title: PEGylated carboxyhemoglobin bovine (SANGUINATE): results of a phase I clinical trial

Author: Misra H, Lickliter J, Kazo F, Abuchowski A

Journal: Artificial Organs 2014 Aug;38(8):702-7

DOI: 10.1111/aor.12341

EPub: 12AUG2014

PMID: 25113835

Link: https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1111%2Faor.12341


Title: Toxicology and Safety Determination for a Novel Therapeutic Dual Carbon Monoxide and Oxygen Delivery Agent

Author: Misra H, Kazo F, Newmark JA

Journal: Clinical Toxicology 2014, 4:4

DOI: 10.4172/2161-0495.1000205

EPub: 14JUL2014

Link: Toxicology_Safety_Determination_for_Novel_Therapeutic-Dual_Carbon_Monoxide-Oxygen_Delivery-_Agent.pdf


Title: Carbon monoxide form of PEGylated hemoglobin protects myocardium against ischemia/reperfusion injury in diabetic and normal mice

Author: Ananthakrishnan R, Li Q, O’Shea KM, Quadri N, Wang L, Abuchowski A, Schmidt AM, Ramasamy R

Journal: Artif Cells Nanomed Biotechnol. 2013 Dec;41(6):428-36

DOI: 10.3109/21691401.2012.762370

EPub: 23JAN2013

PMID: 23342967

Link: https://www.ncbi.nlm.nih.gov/pubmed/?term=10.3109%2F21691401.2012.762370


Title: Early Treatment of Transient Focal Cerebral Ischemia with Bovine PEGylated Carboxy Hemoglobin Transfusion

Author: Klaus JA, Kibler KK, Abuchowski A, Koehler RC

Journal: Artificial cells, blood substitutes, and immobilization biotechnology. 2010;38(5):223-229

DOI: 10.3109/10731199.2010.488635

PMID: 20486873

Link: https://www.ncbi.nlm.nih.gov/pubmed/?term=10.3109%2F10731199.2010.488635


Title: Transfusion of hemoglobin-based oxygen carriers in the carboxy state is beneficial during transient focal cerebral ischemia

Author: Zhang J, Cao S, Kwansa H, Crafa D, Kibler KK, Koehler RC

Journal: Journal of Applied Physiology. 2012;113(11):1709-1717

DOI: 10.1152/japplphysiol.01079.2012

EPub: 04OCT2012

PMID: 23042910

Link: https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1152%2Fjapplphysiol.01079.2012